Curis, Inc. (CRIS) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a mixed picture. While there is a positive net income due to a one-time gain, the company faces ongoing financial losses and operational risks. The lack of revenue for 2026 and dependence on future financing are concerns. However, the optimistic guidance for clinical trials and reduced expenses are positive. The Q&A session highlights challenges in trial enrollment and management's reluctance to provide specifics, adding uncertainty. Given these factors, the stock price is expected to remain stable in the short term, leading to a neutral sentiment rating.
Key Financial Performance
Net Income (Q4 2025) $19.4 million or $1.23 per share, compared to a net loss of $9.6 million or $1.25 per share in Q4 2024. The net income in Q4 2025 is due to a $27.2 million onetime noncash gain from the sale of Erivedge to Oberland.
Net Loss (Full Year 2025) $7.6 million or $0.58 per share, compared to a net loss of $43.4 million or $6.88 per share in 2024. The improvement is attributed to the onetime noncash gain and reduced expenses.
Research and Development Expenses (Q4 2025) $5.8 million, compared to $9 million in Q4 2024. The decrease is primarily due to lower manufacturing, employee-related, and clinical costs.
Research and Development Expenses (Full Year 2025) $28.3 million, compared to $38.6 million in 2024. The decrease is primarily due to lower manufacturing, employee-related, and clinical costs.
General and Administrative Expenses (Q4 2025) $2.9 million, compared to $3.4 million in Q4 2024. The decrease is primarily due to lower employee-related costs.
General and Administrative Expenses (Full Year 2025) $14 million, compared to $16.8 million in 2024. The decrease is primarily due to lower employee-related costs.
Cash and Cash Equivalents (as of December 31, 2025) Includes initial gross proceeds of $20.2 million received in January 2026 and expected gross proceeds of up to an additional $20.2 million from the exercise of January 2026 PIPE financing Series B warrants. This should enable planned operations into the second half of 2027.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
TakeAim Lymphoma Study: Progress in primary CNS lymphoma, a rare and difficult-to-treat NHL subtype. The study evaluates emavusertib in combination with ibrutinib after progression on BTKi therapy. Collaborative discussions with FDA and EMA aim for accelerated submissions in the U.S. and Europe.
Emavusertib in CLL: Exploring emavusertib's potential to improve treatment for CLL patients by achieving deeper responses and potentially complete remission when combined with BTKi. Proof-of-concept study initiated in the U.S. and Europe, with initial data expected at the ASH Annual Meeting in December.
AML Triplet Study: Presented data on combining emavusertib with azacitidine and venetoclax in AML patients. Initial results show 5 of 8 evaluable patients achieved MRD conversion, indicating potential for undetectable disease.
Market Expansion for Emavusertib: Clinical sites activated in the U.S. and Europe for CLL proof-of-concept study, aiming to expand emavusertib's application in NHL subtypes.
Financial Performance: Reported net income of $19.4 million for Q4 2025 due to a $27.2 million one-time noncash gain from the sale of Erivedge. Annual net loss reduced to $7.6 million in 2025 from $43.4 million in 2024.
Cost Management: R&D expenses decreased to $5.8 million in Q4 2025 from $9 million in Q4 2024. Annual R&D expenses reduced to $28.3 million in 2025 from $38.6 million in 2024. G&A expenses also decreased year-over-year.
Cash Position: Cash and cash equivalents, along with expected proceeds from PIPE financing, are projected to support operations into the second half of 2027.
Strategic Shift in CLL Treatment: Aiming to change the treatment paradigm in CLL by combining emavusertib with BTKi for deeper responses, complete remission, and time-limited treatment.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company is conducting studies that require regulatory approval for accelerated submissions in the U.S. and Europe. Any delays or issues in obtaining these approvals could impact the company's ability to bring its treatments to market.
Clinical Trial Risks: The success of the company's treatments depends on the outcomes of ongoing clinical trials, including the TakeAim Lymphoma study and proof-of-concept study in CLL. Any unfavorable results or delays in these trials could adversely affect the company's strategic objectives.
Market Adoption Risks: The company aims to change the treatment paradigm for CLL and NHL patients by introducing emavusertib. However, achieving market adoption depends on demonstrating significant improvements over existing BTKi therapies, which may be challenging.
Financial Risks: Although the company reported a net income for Q4 2025 due to a one-time noncash gain, it has experienced net losses for the year. Sustained financial losses could impact its ability to fund operations and future research.
Operational Risks: The company's ability to sustain operations into the second half of 2027 depends on expected proceeds from financing activities. Any shortfall in these proceeds could disrupt planned operations.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
TakeAim Lymphoma Study: The study is progressing well, with expectations to support accelerated submissions in both the U.S. and Europe after collaborative discussions with the FDA and EMA.
Emavusertib in CLL: Plans to expand emavusertib studies into additional NHL subtypes, with a focus on improving treatment outcomes for CLL patients. A proof-of-concept study is underway, with initial data expected at the ASH Annual Meeting in December.
AML Triplet Study: Encouraging initial data from the study combining emavusertib with azacitidine and venetoclax, showing potential for MRD conversion in AML patients. Further advancements are anticipated in 2026.
Financial Outlook: Cash and cash equivalents, along with expected proceeds from financing, are projected to support operations into the second half of 2027.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How is the company prioritizing trial progress between PCNSL, CLL, and AML?
A:The company is prioritizing NHL (PCNSL and CLL) ahead of AML. PCNSL is being prioritized for registrational approval and is on track, while CLL is in its early stages with initial data expected by the end of the year. AML is currently in the planning phase, with further steps dependent on additional resources.
Q:Can you provide an update on PCNSL enrollment?
A:Enrollment is on track, but the process is challenging due to the rarity of patients. The company expects full enrollment within 12-18 months, with potential data to discuss by the end of the year. Full enrollment and subsequent filing are anticipated around 2027.
Q:Should we model no meaningful revenue for 2026 before product approval?
A:Yes, there will be no meaningful revenue for 2026. The revenue stream from Erivedge ended in November 2025, and the remaining royalties were sold to Oberland. This has no significant impact on cash flows.
Q:What kind of data should be expected at ASH '26 on CLL, and how would success be determined?
A:The company plans to present initial data at ASH '26, focusing on execution and patient enrollment. Success would be defined by achieving deeper responses, such as complete remission and MRD negativity, by inhibiting both the BCR and TLR pathways. The company is optimistic but still in the learning phase.
Q:Has the first patient been dosed in the CLL study?
A:The company has not disclosed whether the first patient has been dosed. They are in the process of initiating the study, with sites opening in the U.S. and Europe, and aim to have data by ASH '26.
Q:Review of Unclear Management Responses
A:Management avoided providing specific enrollment numbers for PCNSL, stating only that enrollment is on track. They also did not disclose whether the first patient has been dosed in the CLL study, opting to focus on broader updates rather than month-by-month reporting.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BTKi decade
BTKi therapy
BTKi treatment
CLL blockade
CLL risk
CLL update
Dr Chief
Europe ASH
Europe progress
Lymphoma study
MRD disease
MRD site
NHL subtype
NHL subtypes
Officer Dr
PCNSL proof
TakeAim Lymphoma
Update progress
ability remission
addition azacitidine
afternoon
azacitidine venetoclax
concept study
disease potential
emavusertib azacitidine
life
paradigm CLL
patient BTKi
potential treatment
proof concept
remission patient
standard care
study patient
treatment paradigm
CRIS Transcript
Curis, Inc. (CRIS) Q4 2025 Earnings Call Transcript
Unknown3-19
The earnings call reveals a mixed picture. While there is a positive net income due to a one-time gain, the company faces ongoing financial losses and operational risks. The lack of revenue for 2026 and dependence on future financing are concerns. However, the optimistic guidance for clinical trials and reduced expenses are positive. The Q&A session highlights challenges in trial enrollment and management's reluctance to provide specifics, adding uncertainty. Given these factors, the stock price is expected to remain stable in the short term, leading to a neutral sentiment rating.
Curis, Inc. (CRIS) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call highlights several risks, including regulatory challenges, financial constraints, and competition. The company reported a net loss, though reduced compared to the previous year, and has limited cash reserves. The Q&A section reveals a lack of detailed guidance and an emphasis on securing additional capital, indicating financial strain. Despite some positive clinical updates, the overall sentiment leans negative due to financial and strategic uncertainties.
Curis, Inc. (CRIS) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript
Neutral9-11
Curis, Inc. (CRIS) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call presents a mixed picture: while there are positive elements such as decreased expenses and a cash runway into 2026, the net losses and lack of specific guidance in certain areas temper enthusiasm. The Q&A section reveals confidence in ongoing studies but lacks clarity in some responses. The absence of a market cap limits the assessment of stock reaction sensitivity. Given these factors, the overall sentiment remains neutral, with no strong catalysts to drive significant short-term stock movement.
CRIS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
